<DOC>
	<DOCNO>NCT01134484</DOCNO>
	<brief_summary>Thalidomide-Dexamethasone ( TD ) standard induction therapy Multiple Myeloma ( MM ) . The present study design compare TD VELCADE-Thalidomide-Dexamethasone ( VTD ) induction therapy preparation , consolidation , melphalan-based double autologous stem cell transplantation previously untreated patient age ≤65 year symptomatic MM . Primary study endpoint rate complete response ( CR ) plus near-complete response ( nCR ) induction treatment . Secondary endpoint include rate CR plus nCR double transplantation subsequent consolidation therapy , time progression ( TTP ) , progression-free survival ( PFS ) , overall survival ( OS ) toxicity profile VTD TD .</brief_summary>
	<brief_title>VELCADE-Thalidomide-Dexamethasone ( VTD ) vs Thalidomide-Dexamethasone ( TD ) Incorporated Into Double Autotransplantation Untreated Multiple Myeloma ( MM )</brief_title>
	<detailed_description>This prospective phase 3 trial aim evaluate whether , comparison standard TD , addition Velcade TD increase rate CR nCR 15 % 30 % , respectively . For purpose , symptomatic patient age 18-65 year previously untreated MM quantifiable M-protein serum urine randomize ( 1:1 ) receive induction therapy comprise three 3-week cycle Velcade 1.3 mg/sqm , day 1 , 4 , 8 , 11 , thalidomide 100 mg , day 1-14 , cycle 1 , 200 mg daily , dexamethasone 40 mg , day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 , thalidomide dexamethasone ( schedule dosage VTD ) . Randomization VTD TD stratify accord International Staging System disease stage diagnosis . Following induction therapy , patient arm receive cyclophosphamide ( 4 g/sqm , day 0 granulocyte colony-stimulating factor , 10 μcg/kg/day , day +2 ) collect autologous peripheral blood stem cell ( minimum threshold CD34+ cell : 4 x 10^6/kg ) two subsequent course stem cell-supported high dose melphalan ( 200 mg/sqm ) , 3 6 month apart . Upon neutrophil ( ≥1 x 10^9/L ) platelet ( ≥75 x 10^9/L ) recovery follow first autotransplantation , patient receive thalidomide ( 100 mg daily ) dexamethasone ( 40 mg , day 1-4 every 4 week ) bridge therapy day second transplantation . Patients initially randomize receive VTD TD induction therapy plan receive two 5-week cycle VTD ( Velcade 1.3 mg/sqm , day 1 , 8 , 15 , 22 ; thalidomide 100 mg daily ; dexamethasone 40 mg , day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 ) TD ( thalidomide 100 mg daily ; dexamethasone 40 mg , day 1-4 20-23 ) consolidation therapy , start 3 month last transplant . Maintenance therapy comprise dexamethasone 40 mg , day 1-4 , repeat monthly relapse progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis symptomatic MM base standard criterion . No prior current systemic therapy MM , include steroid . At least 18 year less 65 year age . Presence quantifiable M protein serum ( e.g . great 1 g/dL IgG MM , great 0.5 g/dL IgA IgD MM ) urine ( e.g . great 200 mg/day BJ MM ) . Karnofsky performance status ( PS ) least 60 % . Willing able comply protocol requirement . Agreement male female patient follow risk management program establish prevention pregnancy , include double method contraception betaHCG test woman childbearing potential contraception male . Adequate organ function , include heart , liver , kidney ( serum creatinine le 2 mg/dL ) Platelet count least 70 x 10/mcL absolute neutrophil count least 1 x 10/mcl Exclusion criterion : Diagnosis asymptomatic MM MGUS base standard criterion . Diagnosis nonsecretory MM . Diagnosis AL Amyloidosis . Prior current systemic therapy MM , include steroid ( exception bisphosphonates ) . Patient receive investigational drug within 30 day enrollment . Female subject pregnant breastfeed Patient Grade 2 high peripheral neuropathy ( NCI criterion ) . Patient prior history thrombosis venous thromboembolism pulmonary embolism . Patient previous diagnosis antiphospholipid antibody lupus anticoagulant , factor V Leiden mutation , prothrombin G21210A mutation , antithrombin , protein C S deficiency . Patient clear indication receive specific antiplatelet therapy ( e.g . clopidogrel , ticlopidine ) . Patient clear indication receive longterm anticoagulant therapy ( e.g . prosthetic heart valve , atrial fibrillation ) . Active bleeding high risk bleeding ( gastrointestinal bleeding within past 12 month ; endoscopic diagnosis peptic ulcer disease ulcerative esophagitis within past 6 month unless document endoscopic evidence healing ; intracranial bleeding within past year ; amyloidosis ; know bleed diathesis ) . Seropositive HIV , active hepatitis A , B C infection . Poorly control hypertension diabetes mellitus ( receive antidiabetic agent , subject must stable dose least 3 month start therapy ) serious medical psychiatric condition could interfere adherence completion study . Patient hypersensitivity bortezomib , boron mannitol . Serious medical psychiatric illness likely interfere participation clinical study Previous concurrent malignancy sit , exception appropriately treat localized epithelial skin cervical cancer . Patients remote history ( &gt; 5 year ) cure tumor may enter . Receipt extensive radiation therapy , systemic chemotherapy , antineoplastic therapy within 4 week enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>autologous stem cell transplantation</keyword>
	<keyword>complete remission</keyword>
	<keyword>bortezomib</keyword>
	<keyword>thalidomide</keyword>
	<keyword>progression free survival</keyword>
	<keyword>induction consolidation therapy</keyword>
</DOC>